JBC INTERFERin siRNA transfection reagent

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
QUICK SEARCH:   [advanced]


     

A more recent version of this article appeared on January 2, 2004
This Article
Right arrow Full Text (Accepted Manuscript)
Right arrow All Versions of this Article:
279/1/509    most recent
M308806200v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Deval, J.
Right arrow Articles by Canard, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Deval, J.
Right arrow Articles by Canard, B.

Papers In Press, published online ahead of print October 9, 2003
J. Biol. Chem, 10.1074/jbc.M308806200
Submitted on August 8, 2003
Revised on October 1, 2003
Accepted on October 9, 2003

Mechanistic basis for reduced viral and enzymatic fitness of HIV-1 reverse transcriptase containing both K65R and M184V mutations

Jerome Deval, Kirsten L. White, Michael D. Miller, Neil T. Parkin, Jerome Courcambeck, Philippe Halphon, Boulbaba Selmi, Joelle Boretto, and Bruno Canard

Centre National de la Recherche Scientifique, Université Aix-Marseille I and II, UMR 6098, 13288, Marseille Cedex 09

Corresponding Author: bruno{at}afmb.cnrs-mrs.fr

HIV-1 drug resistance mutations are often inversely correlated with viral fitness, which remains poorly described at the molecular level. Some resistance mutations can also suppress resistance caused by other resistance mutations. We report the molecular mechanisms by which a virus resistant to lamivudine with the M184V reverse transcriptase mutation shows increased susceptibility to tenofovir and can suppress the effects of the tenofovir resistance mutation K65R. Additionally, we report how the decreased viral replication capacity of resistant viruses is directly linked to their decreased ability to use natural nucleotide substrates and that combination of the K65R and M184V resistance mutations leads to greater decreases in viral replication capacity. All together, these results define at the molecular level how nucleoside-resistant viruses can be driven to reduced viral fitness.




This article has been cited by other articles:


Home page
 J. Biol. Chem.Home page
V. K Jamburuthugoda, J. M. Santos-Velazquez, M. Skasko, D. J. Operario, V. Purohit, P. Chugh, E. A. Szymanski, J. E. Wedekind, R. A. Bambara, and B. Kim
Reduced dNTP Binding Affinity of 3TC-resistant M184I HIV-1 Reverse Transcriptase Variants Responsible for Viral Infection Failure in Macrophage
J. Biol. Chem., April 4, 2008; 283(14): 9206 - 9216.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
S. Zelina, C.-W. Sheen, J. Radzio, J. W. Mellors, and N. Sluis-Cremer
Mechanisms by Which the G333D Mutation in Human Immunodeficiency Virus Type 1 Reverse Transcriptase Facilitates Dual Resistance to Zidovudine and Lamivudine
Antimicrob. Agents Chemother., January 1, 2008; 52(1): 157 - 163.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Microbiol. Rev.Home page
C. Dykes and L. M. Demeter
Clinical Significance of Human Immunodeficiency Virus Type 1 Replication Fitness
Clin. Microbiol. Rev., October 1, 2007; 20(4): 550 - 578.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
A. Frangeul, K. Barral, K. Alvarez, and B. Canard
In Vitro Suppression of K65R Reverse Transcriptase-Mediated Tenofovir- and Adefovir-5'-Diphosphate Resistance Conferred by the Boranophosphonate Derivatives
Antimicrob. Agents Chemother., September 1, 2007; 51(9): 3162 - 3167.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
D. Perez-Bercoff, S. Wurtzer, S. Compain, H. Benech, and F. Clavel
Human Immunodeficiency Virus Type 1: Resistance to Nucleoside Analogues and Replicative Capacity in Primary Human Macrophages
J. Virol., May 1, 2007; 81(9): 4540 - 4550.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
N. Sluis-Cremer, C.-W. Sheen, S. Zelina, P. S. A. Torres, U. M. Parikh, and J. W. Mellors
Molecular Mechanism by Which the K70E Mutation in Human Immunodeficiency Virus Type 1 Reverse Transcriptase Confers Resistance to Nucleoside Reverse Transcriptase Inhibitors
Antimicrob. Agents Chemother., January 1, 2007; 51(1): 48 - 53.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
N. A. Margot, J. M. Waters, and M. D. Miller
In Vitro Human Immunodeficiency Virus Type 1 Resistance Selections with Combinations of Tenofovir and Emtricitabine or Abacavir and Lamivudine
Antimicrob. Agents Chemother., December 1, 2006; 50(12): 4087 - 4095.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
H. Dutartre, C. Bussetta, J. Boretto, and B. Canard
General Catalytic Deficiency of Hepatitis C Virus RNA Polymerase with an S282T Mutation and Mutually Exclusive Resistance towards 2'-Modified Nucleotide Analogues
Antimicrob. Agents Chemother., December 1, 2006; 50(12): 4161 - 4169.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
U. M. Parikh, L. Bacheler, D. Koontz, and J. W. Mellors
The K65R Mutation in Human Immunodeficiency Virus Type 1 Reverse Transcriptase Exhibits Bidirectional Phenotypic Antagonism with Thymidine Analog Mutations.
J. Virol., May 1, 2006; 80(10): 4971 - 4977.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
C. Delaunay, F. Brun-Vezinet, R. Landman, G. Collin, G. Peytavin, A. Trylesinski, P. Flandre, M. Miller, D. Descamps, and the Tonus Trial Study Group
Comparative Selection of the K65R and M184V/I Mutations in Human Immunodeficiency Virus Type 1-Infected Patients Enrolled in a Trial of First-Line Triple-Nucleoside Analog Therapy (Tonus IMEA 021)
J. Virol., August 1, 2005; 79(15): 9572 - 9578.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Microbiol.Home page
J. Weber, B. Chakraborty, J. Weberova, M. D. Miller, and M. E. Quinones-Mateu
Diminished Replicative Fitness of Primary Human Immunodeficiency Virus Type 1 Isolates Harboring the K65R Mutation
J. Clin. Microbiol., March 1, 2005; 43(3): 1395 - 1400.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
J. Deval, K. Alvarez, B. Selmi, M. Bermond, J. Boretto, C. Guerreiro, L. Mulard, and B. Canard
Mechanistic Insights into the Suppression of Drug Resistance by Human Immunodeficiency Virus Type 1 Reverse Transcriptase Using {alpha}-Boranophosphate Nucleoside Analogs
J. Biol. Chem., February 4, 2005; 280(5): 3838 - 3846.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
F. Bouchonnet, E. Dam, F. Mammano, V. de Soultrait, G. Hennere, H. Benech, F. Clavel, and A. J. Hance
Quantification of the Effects on Viral DNA Synthesis of Reverse Transcriptase Mutations Conferring Human Immunodeficiency Virus Type 1 Resistance to Nucleoside Analogues
J. Virol., January 15, 2005; 79(2): 812 - 822.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
J. Deval, J.-M. Navarro, B. Selmi, J. Courcambeck, J. Boretto, P. Halfon, S. Garrido-Urbani, J. Sire, and B. Canard
A Loss of Viral Replicative Capacity Correlates with Altered DNA Polymerization Kinetics by the Human Immunodeficiency Virus Reverse Transcriptase Bearing the K65R and L74V Dideoxynucleoside Resistance Substitutions
J. Biol. Chem., June 11, 2004; 279(24): 25489 - 25496.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
K. L. White, J. M. Chen, N. A. Margot, T. Wrin, C. J. Petropoulos, L. K. Naeger, S. Swaminathan, and M. D. Miller
Molecular Mechanisms of Tenofovir Resistance Conferred by Human Immunodeficiency Virus Type 1 Reverse Transcriptase Containing a Diserine Insertion after Residue 69 and Multiple Thymidine Analog-Associated Mutations
Antimicrob. Agents Chemother., March 1, 2004; 48(3): 992 - 1003.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2003 by the American Society for Biochemistry and Molecular Biology.